Role of natural polymers in the development of multiparticulate systems for colon drug targeting

Systematic Reviews in Pharmacy

Volumn 1, Issue 1, 2010, Pages 79-85

  Das, S ^a   Deshmukh, R ^b   Jha, A K ^a  

^a Shri Vile Parle Kelavani Mandal's Narsee Monjee Institute of Management Studies   (India)

^b Shri Shankaracharya Group of Institution   (India)

Author keywords

bioadhesive; colon; Multiparticulate; polysaccharides

Indexed keywords

ALGAROBA; ALGINIC ACID; AMYLOSE; CELLULOSE; CHITOSAN; CHONDROITIN SULFATE; CORTICOSTEROID DERIVATIVE; CURDLAN; CYCLODEXTRIN; DEXTRAN; GLYCERYL TRINITRATE; GONADORELIN DERIVATIVE; GUAR GUM; HYALURONIC ACID; IBUPROFEN; INULIN; ISOSORBIDE; METOPROLOL; METRONIDAZOLE; NANOPARTICLE; OXPRENOLOL; PECTIN; POLYMER; SCLEROGLUCAN; STARCH;

BIOADHESION; BIODEGRADATION; COLONIC DRUG DELIVERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG METABOLISM; DRUG PELLET; DRUG SOLUBILITY; DRUG TARGETING; EMBEDDING; HUMAN; HYDROGEL; PRIORITY JOURNAL; REVIEW; STOMACH PH;

EID: 79952924305     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.59516     Document Type: Review

References (69)

1. Davis SS. Overcoming barriers to the oral administration of peptide drugs. Trends Pharm Sci 1990;11:353-5. (Pubitemid 20262457)
2. Vandenmooter G, Kinget R. Oral colon-specific drug delivery: A review. Drug Delivery 1995;2:81-93.
3. Ashford M, Fell JT. Targeting drugs to the colon: Delivery systems for oral administration. J Drug Target 1994;2:241-58.
4. Devereux JE, Newton JM, Short MB. The influence of density on the gastrointestinal transit of pellets. J Pharm Pharmacol 1994;42:500-1.
5. Hunter E, Fell JT, Sharma H. The gastric emptying of pellets contained in hard gelatin capsules. Drug Dev Ind Pharm 1982;8:751-7. (Pubitemid 12068919)
6. Meier R, Beglinge C, Dederding JP, Meyer-Wyss B, Fumagalli B, Rowedder A, et al. Influence of age, gender, hormonal status and smoking habits on colonic transit time. Neurogastroenterol Motil 1995;7:235-8.
7. Price JMC, Davis SS, Sparrow RA, Wilding IR. The effect of meal composition on the gastrocolonic response: Implications for drug delivery to the colon. Pharm Res 1993;10:722-726 (Pubitemid 23152319)
8. Pinhasi A, Gomberg M, Avramoff A. US200467030442004.
9. Brahma NS. Modified-release solid formulations for colonic delivery. Recent Pat Drug Deliv Formul 2007;1:53-63.
10. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
11. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7. (Pubitemid 32234805)
12. Fallingborg J, Christensen LA, Jacobson BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993;38:89-93.
13. Kramer A, Turk S, Vrecer F. Statistical optimization of diclofenac sodium sustained release pellets coated with polymethacrylic films. Int J Pharm 2003;256:43-52. (Pubitemid 36412138)
14. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharmacol 1985;37:874-7. (Pubitemid 16222321)
15. Davis SS. Assessment of gastrointestinal transit and drug absorption. Novel drug delivery and its therapeutic application. Wiley Cichester; 1989. p. 89-101.
16. Davis SS. Overcoming barriers to the oral administration of peptide drugs. Trends Pharm Sci 1990;11:353-5. (Pubitemid 20262457)
17. Meyer JH, Dressman J, Fink AS, Amidon G. Effect of size and density on gastric emptying of indigestible solids. Gastroenterology 1985;89:805-13. (Pubitemid 15015296)
18. Rodriguez M, Vila-Jato JL, Torres D. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J Control Rel 1998;55:67-77. (Pubitemid 28477565)
19. Asghar LFA, Chandran S. Multiparticulate formulation, approach to colon specific drug delivery: Current perspectives. J Pharm Pharmaceut Sci 2006;9:327-38. (Pubitemid 46614339)
20. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Microsphere design for the colonic delivery of 5-Fluorouracil. J Control Release 2003;90:313-22. (Pubitemid 36859963)
21. Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. J Drug Deliv 2004;11:201-7. (Pubitemid 38720417)
22. Beckert T, Petereit HU, Dressman J, Rudolph M. US200568972052005.
23. Healey JN. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. Scand J Gastroenterol Suppl 1990;172:47-51. (Pubitemid 20206667)
24. Watts PJ, Illum L. Colonic drug delivery. Drug Develop Ind Pharm 1997;23:893-913. (Pubitemid 27406363)
25. Chu JS. Advances in colon specific drug delivery system employing the CODES TM, The Drug Delivery Companies Report, autumn/Winter Pharmaventures Ltd; 2003.
26. Krogars K, Heinamaki J, Vesalahti J, Marvola M. Antikainen O, Yliruusi J, et al. Extrusion spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int J Pharm 2000;199:187-94. (Pubitemid 30236190)
27. Nyknen P, Krogars K, Skkinen M, Heinmki J, Jrjensson H, Veski P, et al. Organic acids as excipients in matrix granules for colon-specific drug delivery. Int J Pharm 1999;184:251-61. (Pubitemid 29317659)
28. Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. J Drug Deliv 2004;11:201-7. (Pubitemid 38720417)
29. Lenaert V, Gurny R. Bioadhesive drug delivery systems. Boca Raton: CRC Press; 1990. p. 25-42.
30. Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for Site-Specific drug delivery to the colon. J Pharm Pharmaceut Sci 2007;10:86-128. (Pubitemid 46692379)
31. Englyst HN, MacFarlane GT. Breakdown of resistant and readily digestible starch of human gut bacteria. J Sci Food Agric 1986;37:699-706.
32. Cummings JH, Milojevic S, Harding M, Coward WA, Gibson GR, Botham RL, et al. In-vivo studies of amylose and ethylcellulose coated 13 C glucose microspheres as a model for drug delivery to the colon. J Control Release 1996;40:123-31.
33. Allwood MC, Ring SG, Archer DB, Davies JD, Touitou E, Rubinstein A. Delayed release composition comprising glassy amylase-to delay active agent release in acidic-to-weakly basic aqueous media but permitting release after enzymatic hydrolysis, e.g. in the colon, Capsule for targeted delivery of drugs to the colon containing absorption promoter and coated with polymer insoluble at pH below 7. 1989;EP343993-a, A61k-009/22.
34. Cummings JH, Southgate DA, Branch WJ, Wiggins HS, Houston H, Jenkins DJ, et al. The digestion of pectin in human gut and its effect on calcium absorption and large bowel function. Br J Nutr 1979;41:477-85. (Pubitemid 9192003)
35. Englyst HN. Digestion of the polysaccharides of potato in the small intestine of man. Am J Clin Nutr 1987;45:423-31. (Pubitemid 17020809)
36. Dysseler BS, Hoffen MJ. Inulin. An alternative dietary fiber: Properties and quantitative analysis. Eur J Clin Nutr 1995;49:S145-52.
37. McKeller RC, Modler HW. Metabolism of fructooligosaccharides by Biffidobacterium spp. Appl Microbiol Biotechnol 1989;31;537-41.
38. Wang X, Gibson GR. Effects of the In vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine. J Appl Bacterol 1993;75:373-80. (Pubitemid 23305383)
39. Vervoort L, Kinget R. In vitro degradation by colonic bacteria of inulin incorporated in Eudragit films. Int J Pharm 1996;129:185-90. (Pubitemid 26097984)
40. Vervoort L, Van den Mooter G, Augustijns P, Busson R, Toppet S, Kinget R. Inulin hydrogels as carrier for colonic drug targeting. Pharm Res 1997;14:1730-6.
41. Bauer KH, Kesselhut JF. Novel pharmaceutical excipients for colon targeting. STP Pharm Sci 1995;5:54-9.
42. Raghavan CV, Muthulingam C, Leno Jenita JA, Ravi TK. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting. Int J Pharm 2002;50:92-895.
43. Basit AW. Advances in colonic drug delivery. Drugs 2005;65:1991-2007. (Pubitemid 41324059)
44. Sinha VR, Kumria R. Polysaccharides in colon specific drug delivery. Int J Pharm 2001;224:19-38. (Pubitemid 32706482)
45. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Deliv Rev 2005;57:247-65. (Pubitemid 39536101)
46. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, et al. Cross-linked guar gum microspheres: A viable approach for improved delivery of anticancer drugs for the treatment of colorectal cancer. AAPS Pharm Sci Tech 2006;7:74.
47. Thimma RT, Tammishetti S. Barium chloride crosslinked carboxymethyl guar gum beads for gastrointestinal drug delivery. J Appl Poly Sci 2001;82:3084-90. (Pubitemid 33025780)
48. Tomolin J, Taylor JS, Read NW. The effect of mixed faecal bacteria on a selection of viscous polysaccharide in vitro. Nutr Rep Int 1989;39:121-35. (Pubitemid 19041309)
49. Bayliss CE, Houston AP. Degradation of guargum by faecal bacteria. Appl Environ Microbiol 1986;48:626-32.
50. Macfarlane GT, Hay S, Macfarlane S, Gibson GR. Effect of different carbohydrates on growth polysaccharidases and glycosidase production of Bacteroides ovatus in batch and continuous culture. J Appl Bacteriol 1990;68:179-87. (Pubitemid 20129668)
51. Chourasia MK, Jain SK. Potential of guar gum microspheres for target specific drug release to colon. J Drug Target 2004;2:1-8.
52. Stubbe B, Maris B, Van den Mooter G, Demeester J. The in vitro evaluation of azo containing polysaccharide gels for colon delivery. J Control Rel 2001;75:103-14. (Pubitemid 32635201)
53. Wastenson A. Properties of fractionated chondroitin sulfate form ox nasal septa. Biochem J 1971;122:477-785.
54. Toledo O, Dietrich CP. Tissue specific distributions of sulfated mucopolysaccharides in mammals. Biochim Biophys Acta 1977;498:114-22. (Pubitemid 8117482)
55. Salyers AA. Energy sources of major intestinal fermentative anaerobes. Am J Clin Nutr 1979;32:158-63.
56. Salyers AA, O'Brien M. Cellular location of enzymes involved in chondroitin sulfate break down by Bacteroides thetaiotaomicron. J Bacteriol 1980;143:772-80. (Pubitemid 10017648)
57. O'Regan M, Martini I, Crescenzi F, De Luca C, Lansing M. Molecular mechanisms and genetics of hyaluronan biosynthesis. Int J Biol Macromol 1994;16:283-6.
58. Fraser JR, Brown TJ, Laurent TC. Catabolism of hyaluronan. In: Lauret TC, editor. The chemistry, biology, and medical applications of hyaluronan and its derivatives. Miami, FL: Portland Press; 1998. p. 85-92.
59. Omrod DJ, Holmes CC, Miller TE. Dietary chitosan inhibits hypercholesterolaemia andantherogensis in the apoliprotein E-deficientmouse model of atherosclerosis. Atherosclerosis 1998;138:329-34. (Pubitemid 28313517)
60. Jain SK, Jain A, Gupta Y, Ahirwar M. Design and development of hydrogel beads for targeted drug delivery to Colon. AAPS Pharm Sci Tech 2007;8:E1-8. (Pubitemid 47103044)
61. Harboe E, Johansen M, Larsen C. Macromolecular prodrugs: VI, Coupling of the highly lipophilic agent naproxen to dextrans and invitro characterization of the conjugates. Farmaci Sci Ed 1988;16:73-85.
62. Harboe E, Larsen C, Johansen M, Olesen HP. Macromoleculer prodrugs: XIV: Absorption characteristics of naproxen after oral administration of dextran T-70-naproxen esterprodrugs in pigs. Int J Pharm 1989a;53:157-65. (Pubitemid 19198384)
63. McLeod AD, Tolentino L, Tozer TN. Glucocorticoid-dextran ester conjugates as potential prodrugs for colon-specific drug delivery, steady state pharmacokinetics in rat. Biopharm Drug Dispos 1994b;15:151-64.
64. McLeod AD, Fedorak RN, Friend DR, Tozer TN, Cu NA. Glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology 1994a;106:405-13. (Pubitemid 24041218)
65. Gerloczy A, Fonagy A, Keresztes P, Perlaky L, Szejtli J. Absorption, distribution, excretion and metabolism of orally administered 14 C-cyclodextrin in rat. Arzneim Forsch/Drug Res 1985;35:1042-7. (Pubitemid 15033420)
66. Flourie B, Molis C, Achour L, Dupas H, Hatat C, Rambaud JC. Fate of-cyclodextrinin the human intestine. J Nutr 1993;123:676-80.
67. McIntosh M, Stone BA, Stanisich VA. Curdlan and other bacterial (1-3)-beta-D-glucans. Appl Microbiol Biotechnol 2005;68:163-73.
68. Shun YL, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res 1992;9:714-90.
69. Giavasis I, Harvey LM, McNeil B. Scleroglucan. Biopolymers. In: De Baets S, Vandamme EJ, Steinbchel A, editors. Wiley-VCH: Weinheim; 2002. p. 37.